Anupam Rasayan makes open offer for 26 percent stake in Bliss GVS at Rs 299/share

Listed Co AcquisitionOpen Offer TriggeredStrategic Transactions View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.3%Reaction day

₹467.60

prior close

₹461.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.2%-3.1% vs market

Pharmaceuticals peers, median of 165sector-1.6%-2.7% vs sector

On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-1.4

15m

-1.7

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.3-1.2-3.1-1.6-2.7

Next day

-1.0-1.9+0.8-2.5+1.4

-1.2-1.4+0.2-2.5+1.3

-2.4-0.1-2.2-1.3-1.1

-3.5-1.4-2.1-2.4-1.2

-2.7-1.0-1.7-1.7-1.0

-0.7-0.4-0.3-2.1+1.4

15d

+4.8+3.2+1.6-0.3+5.1

+19.8+4.4+15.4-1.1+20.9

+48.5+4.6+44.0+0.8+47.7

+37.4-3.6+41.0-6.6+44.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anupam Rasayan India along with PAC Mates Visa Consultancy makes a cash open offer to acquire up to 2.77 crore shares (26 percent of expanded voting capital) of Bliss GVS Pharma at Rs 299 per share. Total consideration up to about Rs 829 crore. Offer opens July 28, 2026 and closes August 10, 2026. SBI Capital Markets is the manager to the offer.

Likely market impact

Public shareholders can tender shares at Rs 299 per share between July 28 and August 10, 2026. Signals likely change in control of Bliss GVS Pharma.